1. Mangal M, Sagar P, Singh H, Raghava GP, Agarwal SM. NPACT: Naturally occurring plant-based anti-cancer compound-activitytarget database. Nucleic Acids Res. 2012; 41: D1124-D1129. doi: 10.1093/nar/gks1047
2. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005; 78: 431-441. doi: 10.1016/j.lfs.2005.09.012
3. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007; 70: 461-477. doi: 10.1021/np068054v
4. David B, Wolfender JL, Dias DA. The pharmaceutical industry and natural products: Historical status and new trends. Phytochemistry Reviews. 2015; 14: 299-315. doi: 10.1007/s1110
5. Kinghorn AD, Chin YW, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. Curr Opin Drug Discov Devel. 2009; 12: 189-196.
6. Goldman A, Kulkarni A, Sengupta S. Methods and compo sitions relating to the treatment of cancer. Google Patents. Website. https://patentimages.storage.googleapis.com/ef/ da/6d/3ae68471b194c8/WO2016033472A1.pdf. 2015. Accessed July 14, 2019.
7. Tan G, Gyllenhaal C, Soejarto D. Biodiversity as a source of anticancer drugs. Curr Drug Targets. 2006; 7: 265-277. doi: 10.2174/138945006776054942
8. Cragg GM, Katz F, Newman DJ, Rosenthal J. The impact of the United Nations convention on biological diversity on natural products research. Nat Prod Rep. 2012; 29: 1407-1423. doi: 10.1039/c2np20091k
9. Berdy J. Bioactive microbial metabolites. J Antibiot (Tokyo). 2005; 58: 1-26. doi: 10.1038/ja.2005.1
10. Krause J, Tobin G. Discovery, development, and regulation of natural products. In: Kulka M, ed. Using Old Solutions to New Problems-Natural Drug Discovery in the 21st Century. London, United Kingdom: IntechOpen; 2013: 3-35. doi: 10.5772/56424
11. Phifer SS, Lee D, Seo EK, et al. Alvaradoins E-N, antitumor and cytotoxic anthracenone C-glycosides from the leaves of alvaradoa haitiensis. J Nat Prod. 2007; 70: 954-961. doi: 10.1021/ np070005a
12. Shnyder SD, Cooper PA, Millington NJ, Gill JH, Bibby MC. Sodium pancratistatin 3, 4-o-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model. J Nat Prod. 2007; 71: 321-324. doi: 10.1021/np070477p
13. Winkel-Shirley B. Flavonoid biosynthesis. A colorful model for genetics, biochemistry, cell biology, and biotechnology. Plant Physiol. 2001; 126: 485-493. doi: 10.1104/pp.126.2.485
14. Li H, Wang Z, Liu Y. Review in the studies on tannins activity of cancer prevention and anticancer. Zhong Yao Cai. 2003; 26: 444-448.
15. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23: 363-398.
16. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev. 2008; 66: 445-454. doi: 10.1111/j.1753-4887.2008.00076.x
17. Greenwell M, Rahman P. Medicinal plants: Their use in anticancer treatment. Int J Pharm Sci Res. 2015; 6: 4103-4112. doi: 10.13040/IJPSR.0975-8232.6(10)
18. Prakash O, Kumar A, Kumar P, Ajeet A. Anticancer potential of plants and natural products: A review. American Journal of Pharmacological Sciences. 2013; 1: 104-115. doi: 10.12691/ajps-1-6-1
19. Boopathy NS, Kathiresan K. Anticancer drugs from marine flora: An overview. Journal of oncology. 2010; 2010: 214186. doi: 10.1155/2010/214186
20. Rothschild LJ, Mancinelli RL. Life in extreme environments. Nature. 2001; 409: 1092-1101. doi: 10.1038/35059215
21. Sarfaraj HM, Sheeba F, Saba A, Khan M. Marine natural products: A lead for Anti-cancer. Indian Journal of Geo-Marine Sciences. 2012; 41(1): 27-39.
22. Kalimuthu S, Se-Kwon K. Cell survival and apoptosis signaling as therapeutic target for cancer: Marine bioactive compounds. Int J Mol Sci.. 2013; 14: 2334-2354. doi: 10.3390/ijms14022334
23. Haefner B. Drugs from the deep: Marine natural products as drug candidates. Drug Discov Today. 2003; 8: 536-544. doi: 10.1016/S1359-6446(03)02713-2
24. Jha R, Zi-Rong X. Biomedical compounds from marine organisms. Mar Drugs. 2004; 2: 123-146. doi: 10.3390/md203123
25. Bull AT, Stach JE. Marine actinobacteria: New opportunities for natural product search and discovery. Trends Microbiol. 2007; 15: 491-499. doi: 10.1016/j.tim.2007.10.004
26. Soria-Mercado IE, Villarreal-Gómez LJ, Rivas GG, Sánchez NEA. Bioactive compounds from bacteria associated to marine algae. In: Sammour R, ed. Biotechnology-Molecular Studies and Novel Applications for Improved Quality of Human Life Croatia. London, United Kingdom: IntechOpen; 2012: 25-44. doi: 10.5772/27842
27. James A. Potential of bioactive compounds from marine actinomycetes against extended specturem of beta lactamase roducing pathogens and cancer cell lines hct 116 and hep g2 an in vitro study. 2016.
28. Amador ML, Jimeno J, Paz-Ares L, Cortes-Funes H, Hidalgo M. Progress in the development and acquisition of anticancer agents from marine sources. Anna Oncol. 2003; 14: 1607-1615. doi: 10.1093/annonc/mdg443
29. Bugni TS, Ireland CM. Marine-derived fungi: A chemically and biologically diverse group of microorganisms. Nat Prod Rep. 2004; 21: 143-163. doi: 10.1039/b301926h
30. Raghukumar C. Marine fungal biotechnology: An ecological perspective. Fungal diversity. 2008; 13: 19-35.
31. Thajuddin N, Subramanian G. Cyanobacterial biodiversity and potential applications in biotechnology. Current science. 2005; 89: 47-57.
32. Varshney A, Singh V. Effects of algal compounds on cancer cell line. J Exp Biol. 2013; 1: 337-352.
33. Costa M, Garcia M, Costa-Rodrigues J, et al. Exploring bioac tive properties of marine cyanobacteria isolated from the Portuguese coast: high potential as a source of anticancer compounds. Mar Drugs. 2013; 12: 98-114. doi: 10.3390/md12010098
34. Gerwick WH, Proteau PJ, Nagle DG, Hamel E, Blokhin A, Slate DL. Structure of curacin A, a novel antimitotic, antiproliferative and brine shrimp toxic natural product from the marine cyanobacterium Lyngbya majuscula. The Journal of organic chemistry. 1994; 59: 1243-1245. doi: 10.1021/jo00085a006
35. Kumar CS, Ganesan P, Suresh P, Bhaskar N. Seaweeds as a source of nutritionally beneficial compounds-a review. Journal of Food Science and Technology. 2008; 45: 1-13.
36. Zakaria NA, Ibrahim D, Sulaiman SF, Supardy A. Assessment of antioxidant activity, total phenolic content and in-vitro toxicity of Malaysian red seaweed, Acanthophora spicifera. J Chem Pharm Res. 2011; 3: 182-191.
37. Lavakumar V, Ahamed K, Ravichandran V. Anticancer and antioxidant effect of Acanthophora spicifera against EAC induced carcinoma in mice. Journal of Pharmacy Research. 2012; 5: 1503-1507.
38. Lee JC, Hou MF, Huang HW, et al. Marine algal natural products with anti-oxidative, anti-inflammatory, and anti-cancer properties. Cancer Cell Int. 2013; 13: 55. doi: 10.1186/1475-2867-13-55
39. Ayyad S-EN, Ezmirly ST, Basaif SA, Alarif WM, Badria AF, Badria FA. Antioxidant, cytotoxic, antitumor, and protective DNA damage metabolites from the red sea brown alga Sargassum sp. Pharmacognosy Res. 2011; 3: 160-165. doi: 10.4103/0974- 8490.85000
40. Zhuang C, Itoh H, Mizuno T, Ito H. Antitumor active fucoidan from the brown seaweed, umitoranoo (Sargassum thunbergii). Biosci Biotechnol Biochem. 1995; 59: 563-567. doi: 10.1271/ bbb.59.563
41. Jiang Z, Okimura T, Yokose T, Yamasaki Y, Yamaguchi K, Oda T. Effects of sulfated fucan, ascophyllan, from the brown Alga Ascophyllum nodosum on various cell lines: A comparative study on ascophyllan and fucoidan. J Biosci Bioeng. 2010; 110: 113- 117. doi: 10.1016/j.jbiosc.2010.01.007
42. Vijayakumar S, Menakha M. Pharmaceutical applications of cyanobacteria-A review. Journal of Acute Medicine. 2015; 5: 15-23. doi: 10.1016/j.jacme.2015.02.004
43. Dhorajiya B, Malani M, Dholakiya B. Extraction and preservation protocol of anti-cancer agents from marine world. Chemical Sciences Journal. 2012; 2012: 1-12.
44. Manilal A, Sujith S, Kiran GS, et al. Biopotentials of seaweeds collected from southwest coast of India. Journal of Marine Science and Technology. 2009; 17: 67-73.doi: 10.51400/2709-6998.1979
45. Shibata T, Fujimoto K, Nagayama K, Yamaguchi K, Nakamura T. Inhibitory activity of brown algal phlorotannins against hyaluronidase. International journal of food science & technology. 2002; 37: 703-709. doi: 10.1046/j.1365-2621.2002.00603.x
46. Amer ME, Abou-Shoer MI, Abdel-Kader MS, El-Shaibany A, Abdel-Salam NA. Alkaloids and flavone acyl glycosides from Acanthus arboreus. Journal of the Brazilian Chemical Society. 2004; 15: 262-266. doi: 10.1590/S0103-50532004000200016
47. Uzma F, Mohan CD, Hashem A, et al. Endophytic fungi-alternative sources of cytotoxic compounds: A review. Front Pharmacol. 2018; 9: 309. doi: 10.3389/fphar.2018.00309
48. Peakman M, Vergani D. Basic and Clinical Immunology E-Book: with STUDENT CONSULT Access. London, UK: Churchill Livingstone; 2009.
49. Doll R, Peto R. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981; 66: 1192-1308.
50. Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer. 2010; 10: 785-794. doi: 10.1038/nrc2934
51. Cragg GM, Newman DJ. Antineoplastic agents from natural sources: Achievements and future directions. Expert Opin Investig Drugs. 2000; 9: 2783-2797. doi: 10.1517/13543784.9.12.2783
52. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5: 219-234. doi: 10.1038/nrd1984
53. Yang W. Fast Viability Assessment of Clostridium Spores: Survival in Extreme environments. [dissertation]. CA, USA: California Institute of Technology; 2010.
54. Cheesbrough M. District Laboratory Practice in Tropical Countries. Cambridge, England, UK: Cambridge University Press; 2006.
55. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story. J Urol. 2008; 179: 53-56. doi: 10.1016/j.juro.2007.08.122
56. Ogita S, Tsuto T, Nakamura K, Deguchi E, Tokiwa K, Iwai N. OK-432 therapy for lymphangioma in children: Why and how does it work? J Pediatr Surg. 1996; 31: 477-480. doi: 10.1016/ s00223468(96)90478-9
57. Roberts NJ, Zhang L, Janku F, et al. Intratumoral injection of clostridium novyi-NT spores induces antitumor responses. Sci Transl Med. 2014; 6: 249ra111. doi: 10.1126/scitranslmed.3008982
58. Wei MQ, Ellem KA, Dunn P, West MJ, Bai CX, Vogelstein B. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J Cancer. 2007; 43: 490-496. doi: 10.1016/j.ejca.2006.10.005
59. Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009; 361: 968-979. doi: 10.1056/NEJMoa0810866
60. Łukasiewicz K, Fol M. Microorganisms in the treatment of cancer: Advantages and limitations. Journal of Immunology Research. 2018; 2018. 1-8. doi: 10.1155/2018/2397808
61. Zhou P, Chen Z, Li H-L, et al. Toxoplasma gondii infection in humans in China. Parasit Vectors. 2011; 4: 165. doi: 10.1186/1756- 3305-4-165
62. Karamati SA, Hassanzadazar H, Bahmani M, Rafieian Kopaei M. Herbal and chemical drugs effective on malaria. Asian Pacific Journal of Tropical Disease. 2014; 4: S599-S601. doi: 10.1016/ S2222-1808(14)60686-1
63. Roos MA, Gennero L, Denysenko T, et al. Microparticles in physiological and in pathological conditions. Cell Biochem Funct. 2010; 28: 539-548. doi: 10.1002/cbf.1695
64. Ryan JT, Ross RP, Bolton D, Fitzgerald GF, Stanton C. Bioactive peptides from muscle sources: Meat and fish. Nutrients. 2011; 3: 765-791. doi: 10.3390/nu3090765
65. Möller NP, Scholz-Ahrens KE, Roos N, Schrezenmeir J. Bioactive peptides and proteins from foods: Indication for health effects. Eur J Nutr. 2008; 47: 171-182. doi: 10.1007/s00394-008- 0710-2
66. Qi F, Li A, Inagaki Y, et al. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol. 2011; 11: 342-349. doi: 10.1016/j.intimp.2010.12.007
67. Conlon JM, Demandt A, Nielsen PF, Leprince J, Vaudry H, Woodhams DC. The alyteserins: Two families of antimicrobial peptides from the skin secretions of the midwife toad Alytes obstetricans (Alytidae). Peptides. 2009; 30: 1069-1073. doi: 10.1016/j.peptides.2009.03.004
68. Conlon JM. Structural diversity and species distribution of host-defense peptides in frog skin secretions. Cell Mol Life Sci. 2011; 68: 2303-2315. doi: 10.1007/s00018-011-0720-8
69. Rozek T, Bowie JH, Wallace JC, Tyler MJ. The antibiotic and anticancer active aurein peptides from the Australian bell frogs litoria aurea and litoria raniformis. Part 2. Sequence determination using electrospray mass spectrometry. Rapid Commun Mass Spectrom. 2000; 14: 2002- 2011. doi: 10.1002/1097-0231(20001115)14:21<_x0032_002:_x003a_AIDRCM128>3.0.CO;2-3
70. van Zoggel H, Hamma-Kourbali Y, Galanth C, et al. Antitumor and angiostatic peptides from frog skin secretions. Amino Acids. 2012; 42: 385-395. doi: 10.1007/s00726-010-0815-9
71. Abdel-Wahab YHA, Power GJ, Flatt PR, Woodhams DC, Rollins-Smith LA, Conlon JM. A peptide of the phylloseptin family from the skin of the frog Hylomantis lemur (Phyllomedusinae) with potent in vitro and in vivo insulin-releasing activity. Peptides. 2008; 29: 2136-2143. doi: 10.1016/j.peptides.2008.09.006
72. Theansungnoen T, Maijaroen S, Jangpromma N, et al. Cationic antimicrobial peptides derived from crocodylus siamensis leukocyte extract, revealing anticancer activity and apoptotic induction on human cervical cancer cells. Protein J. 2016; 35: 202- 211. doi: 10.1007/s10930-016-9662-1
73. He S, Mao X, Zhang T, et al. Separation and nanoencapsulation of antitumor peptides from Chinese three-striped box turtle (Cuora trifasciata). J Microencapsul. 2016; 33: 344-354. doi: 10.1080/02652048.2016.1194904
74. Aneiros A, Garateix A. Bioactive peptides from marine sources: Pharmacological properties and isolation procedures. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 803: 41-53. doi: 10.1016/j.jchromb.2003.11.005
75. Goudet C, Chi CW, Tytgat J. An overview of toxins and genes from the venom of the Asian scorpion Buthus martensi Karsch. Toxicon. 2002; 40: 1239-1258.doi: 10.1016/s0041-0101(02)00142-3
76. Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv. 2007; 4: 175-186. doi: 10.1517/17425247.4.2.175
77. King GF, Hardy MC. Spider-venom peptides: Structure, pharmacology, and potential for control of insect pests. Annu Rev Entomol. 2013; 58: 475-496. doi: 10.1146/annurev-ento-120811-153650
78. Vorontsova OV, Egorova NS, Arseniev AS, Feofanov AV. Haemolytic and cytotoxic action of latarcin Ltc2a. Biochimie. 2011; 93: 227-241. doi: 10.1016/j.biochi.2010.09.016
79. Moreno M, Giralt E. Three valuable peptides from bee and wasp venoms for therapeutic and biotechnological use: Melittin, apamin and mastoparan. Toxins (Basel). 2015; 7: 1126-1150. doi: 10.3390/toxins7041126
80. Gajski G, Garaj-Vrhovac V. Melittin: A lytic peptide with anticancer properties. Environ Toxicol Pharmacol. 2013; 36: 697-705. doi: 10.1016/j.etap.2013.06.009
81. de Azevedo RA, Figueiredo CR, Ferreira AK, et al. Mastoparan induces apoptosis in B16F10-Nex2 melanoma cells via the intrinsic mitochondrial pathway and displays antitumor activity in vivo. Peptides. 2015; 68: 113-119. doi: 10.1016/j.peptides.2014.09.024
82. Vyas VK, Brahmbhatt K, Bhatt H, Parmar U. Therapeutic potential of snake venom in cancer therapy: Current perspectives. Asian Pac J Trop Biomed. 2013; 3: 156-162. doi: 10.1016/S2221- 1691(13)60042-8
83. Calderon LA, Sobrinho JC, Zaqueo KD, et al. Antitumoral activity of snake venom proteins: New trends in cancer therapy. Biomed Res Int. 2014; 2014: 203639. doi: 10.1155/2014/203639
84. Rádis-Baptista G, Oguiura N, Hayashi MAF, et al. Nucleotide sequence of crotamine isoform precursors from a single South American rattlesnake (Crotalus durissus terrificus). Toxicon. 1999; 37: 973-984.doi: 10.1016/s0041-0101(98)00226-8
85. Ma R, Mahadevappa R, Kwok HF. Venom-based peptide therapy: Insights into anti-cancer mechanism. Oncotarget. 2017; 8: 100908-100930. doi: 10.18632/oncotarget.21740